GSKCONS

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on August 09, 2017

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange revised format of Financial Results for the Quarter/year ended March 31, 2017.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Declaration for audit reports with unmodified opinion(s).

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from August 4, 2017 to August 9, 2017 for the purpose of Dividend and Annual General Meeting.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 11, 2017, the Board also recommended a Dividend at the rate of Rs. 70/- per equity share of Rs. 10 each. The Dividend, if approved by the shareholders in the ensuing Annual General Meeting scheduled to be held on August 9, 2017, will be paid to those members whose names appear in the Company's Register of Members and to those persons whose names appear as Beneficial owners as per the details to be furnished by National Securities Depository Limited and Cen

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates, the details of Analyst / Institutional Investors Meeting to be held on Friday, May 12, 2017 is as follows:Type of MeetingConference CallTime of Event1200 hours (IST)Dial - in DetailsMumbai: +91 22 3960 0611Bangalore, Chennai, Hyderabad, Kolkata, Gurugram (NCR), Cochin, Pune, Lucknow, Ahmedabad, Chandigarh 3940 3977*

GlaxoSmithKline Pte Ltd has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that In accordance with the Company's Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from March 21, 2017 and shall end 48 hours after public announcement of the Audited / Un-Audited Financial Results for the Financial Year 2016-17.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors, at its meeting held on February 13, 2017 , the tenure of Mr. Subodh Bhargava as a Non Executive Chairman of the Company has been extended further for a period of one year with effect from March 31, 2017 till March 31, 2018.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended 31-Dec-2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call UpdatesAnalyst / Institutional Investors Meeting to be held on Tuesday, February 14, 2017 at 0930 hrs (IST); Dial in details are : Mumbai: +91 22 3960 0611 ; Bangalore, Chennai, Hyderabad, Kolkata : 3940 3977; Gurgaon (NCR), Cochin, Pune, Lucknow, Ahmedabad, Chandigarh: 3940 3977

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that In accordance with the Company s Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from December 22, 2016 and shall end 48 hours after declaration of Audited / Unaudited Financial Results for the Quarter ending December 31, 2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that In accordance with the Company''s Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from September 15, 2016 and shall end 24 hours after declaration of Audited / Unaudited Financial Results for the Quarter ending September 30, 2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on August 5, 2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that at the Board Meeting held on August 5, 2016, Mr. Anup Dhingra has been appointed as an Executive Director of the Company, with effect from September 1, 2016, in the casual vacancy created by the resignation of Mr. Jaiboy John Phillips, who will hold office till August 31, 2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the August 5, 2016 along with Report of Scrutinizer.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that at the Fifty Seventh Annual General Meeting of the Company held on August 5, 2016, at Nabha (Punjab), Mr. Kunal Kashyap, Mr. P Dwarakanath, Mr. Naresh Dayal, Mr. Mukesh H Butani, Ms. Sangeeta Talwar, Mr. Jaiboy John Phillips and Mr. Vivek Anand were elected as Directors by the shareholders through the system of proportional representation.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that Ms. Shanu Saksena, has been appointed as the Company Secretary and Compliance Officer of the Company as per Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 at the Board Meeting held on August 05, 2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on August 5, 2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that In accordance with the Company s Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from June 24, 2016 and shall end 24 hours after declaration of Audited / Unaudited Financial Results for the Quarter ending June 30, 2016.

The Exchange had sought clarification from the Company with respect to announcement submitted to the Exchange dated June 15, 2016 regarding resumption of operations which were temporary suspended at Company's factory located at Nabha, Patiala - 147201.On basis of above, the Reply of the Company is attached.

The Exchange has sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to announcement submitted to the Exchange dated June 15, 2016 regarding resumption of operations which were temporary suspended at Company's factory located at Nabha, Patiala - 147201On basis of above Company is required to clarify that :1. Financial impact on the Company during such suspension period. The reply from the Company is awaited.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange vide letter dated June 15, 2016 regarding "Resumption of operations".

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the standalone financial results along with the Auditors Report for the period ended 31-Mar-2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that due to certain disruption created by the workforce/ flash strike by the workforce, the management of GlaxoSmithKline Consumer Healthcare Limited has decided to suspend operations temporarily at its factory located at Nabha Patiala- 147201 with effect from the night of May 21, 2016 in the interest of safety and security of its employees and to protect the assets of the factory.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from July 28, 2016 to August 5, 2016 (both days inclusive) for the purpose of Dividend and Annual General Meeting (AGM) of the Company to be held on August 5, 2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on May 17, 2016 has recommended a Dividend at the rate of Rs. 70/- per equity share of Rs. 10 each. The Dividend, if approved by the shareholders in the ensuing Annual General Meeting scheduled to be held on August 5, 2016, will be paid to those members whose names appear in the Company's Register of Members and to those persons whose names appear as Beneficial owners as per the details to be furnished by National Securities Depository Limited and Central Depos

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that Ms. Sonali Khanna, Company Secretary and Compliance Officer of the Company has resigned and the Board of Directors at its meeting held on May 17, 2016, has accepted her resignation and accordingly Ms. Sonali Khanna ceases to be a Company Secretary and Compliance Officer of the Company with effect from the closing hours of May 17, 2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended 31-Mar-2016.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board noted that Horlicks Limited had withdrawn the Nomination of Mr. Jonathan Box and nominated Mr. Joaquin Beneyto Mascaro in his place, as the Director of the Company with effect from May 17, 2016, under Article 97-A of the Articles of Association of the Company. Further, Ms. Sonali Khanna, Company Secretary and Compliance Officer of the Company has resigned and the Board of Directors at its meeting held on May 17, 2016, has accepted her resignation and accordingly Ms. Sonali Khanna ceases to be a Company Secreta

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Schedule of Analyst / Institutional Investor meeting.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Schedule of Analyst/ Institutional Investor Meeting.

Horlicks Limited has submitted to the Exchange vide letter dated April 1, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that in accordance with the Company's Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from March 15, 2016 and shall end 48 hours after public announcement of the Audited/Un-Audited Financial Results for the Financial Year 2015-16.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of Presentation to Analyst/ Institutional Investors

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange vide letter February 03, 2016 regarding "Schedule of Analyst/Institutional Investor Meeting".

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Disclosure under Regulation 30(5) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that In accordance with the Company's Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from December 15, 2015 and shall end 48 hours after public announcement of the Quarterly Financial Results for the third quarter (FY 2015 2016).

GlaxoSmithKline Consumer Healthcare Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that In accordance with the Company''s Policy on Insider Trading, the date of commencement of closing of Trading Window shall be from September 15, 2015 and shall end 48 hours after public announcement of the Quarterly Financial Results for the second quarter for the Financial Year 2015 -2016.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on August 06, 2015.

The Exchange had sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to recent news item captioned "FSSAI orders testing of GSK, ITC fast food brands". The Company has clarified on August 07, 2015 that "We had as on that date not received any communication from FSSAI Authorities regarding our brand Foodles. We will provide all support to the authorities and ensure that we remain in complete compliance with the law. GlaxoSmithKline Consumer Healthcare Ltd is a responsible company driven by values and committed to bring the best for our consumers".

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of the Scrutinizer's Report pursuant to Annual General Meeting held on August 6, 2015.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange a copy of proceedings of Annual General Meeting of the Company held on August 6, 2015 along with a copy of details of voting results as per Clause 35A of the Listing Agreement.